knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 22:04:39 - browse：29

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： iTeos Therapeutics debuts first data on TIGIT

hotspot

WSS

A disappointing year of Humira biosimilars

Do more moles mean more problems? Not so, says new study

Doctors' information doesn't help them choose wisely when sick

Industry veterans launch new biotech VC with $310M

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Readout LOUD podcast: How biotech is using artificial intelligence

focus

knowledge

knowledge

23andMe had bad news about my health. I wish a person had delivered it

What will save rural psychiatry services? Higher Medicaid payments

Moonlake's readout produced a cash windfall. Risks remain

Medicare Advantage proposed rates disappoint insurers

Trump demands the U.S. pay no more for drugs than other countries … again

Antibiotic resistance nearly killed me, so I'm raising awareness of it

The cancer drug shortage isn’t new — and neither are the solutions

A disappointing year of Humira biosimilars

Psychedelics group wrestles with new pharma identity

iTeos Therapeutics debuts first data on TIGIT

Wikipedia

Medicare Advantage proposed rates disappoint insurers

What we’ve learned from the Aduhelm mess

Vaccine advisory panel ACIP left half staffed by HHS

PhRMA lawsuit over Medicare drug price negotiation tossed

PhRMA lawsuit over Medicare drug price negotiation tossed

What will save rural psychiatry services? Higher Medicaid payments

leisure time

knowledge

hotspot

leisure time